Acadian Asset Management
RLAY icon

Acadian Asset Management’s Relay Therapeutics RLAY Stock Holding History

Acadian Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-290,352
Closed -$2.89M – 2201
2026
Q1 		$2.89M Sell
290,352
-166,296
-36% -$1.49M ﹤0.01% 846
2025
Q4 		$3.86M Sell
456,648
-44,590
-9% -$318K 0.01% 723
2025
Q3 		$2.61M Sell
501,238
-293,381
-37% -$1.12M ﹤0.01% 827
2025
Q2 		$2.75M Buy
794,619
+112,591
+17% +$335K 0.01% 749
2025
Q1 		$1.78M Buy
682,028
+653,081
+2,256% +$2.56M 0.01% 788
2024
Q4 		$118K Buy
+28,947
New +$158K ﹤0.01% 1336
2024
Q1 		– Sell
-3,875
Closed -$42K – 1747
2023
Q4 		$42K Buy
+3,875
New +$32.7K ﹤0.01% 1479
2022
Q4 		– Sell
-1,744
Closed -$38K – 1894
2022
Q3 		$38K Buy
+1,744
New +$38.3K ﹤0.01% 1529

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Acadian Asset Management's RLAY Position: Q2 2026 in Review

Acadian Asset Management sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 290,352 shares — an estimated $2.89M sold.

Acadian Asset Management first reported a position in RLAY in Q3 2022 and held it in 8 quarters. The position peaked at $3.86M in Q4 2025. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Acadian Asset Management reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 290,352 Relay Therapeutics shares in Q2 2026, an estimated $2.89M.
  • Acadian Asset Management first reported a position in Relay Therapeutics in Q3 2022 and held it in 8 quarters.
  • Acadian Asset Management's Relay Therapeutics position peaked at $3.86M in Q4 2025.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.